Research Article
Variability in the Management of Superficial Venous Thrombophlebitis across Practitioners Based in North America and the Global Community
Table 4
Anticoagulation trends among practitioners in North America and the global community.
| | Variable | North America, (%) | Global community, (%) | value |
| | Anticoagulation for patients with acute GSV SVT | | | 0.84 | | All patients | 34 (9.3%) | 12 (9.8%) | | | Involvement of >5 cm GSV | 37 (10.1%) | 16 (13.1%) | | | Clot within 10 cm of saphenofemoral junction | 101 (27.7%) | 34 (27.9%) | | | Proximal extension of clot on follow-up visit | 91 (24.9%) | 25 (20.5%) | | | Never | 41 (11.2%) | 15 (12.3%) | | | Other/no answer | 61 (16.7%) | 20 (16.4%) | |
| | Anticoagulation for patients with acute SSV SVT | | | 0.10 | | All patients | 48 (13.2%) | 11 (9%) | | | Involvement of >5 cm SSV | 44 (12%) | 13 (10.7%) | | | Clot with 10 cm of saphenofemoral junction | 68 (18.6%) | 25 (20.5%) | | | Proximal extension of clot on follow-up visit | 75 (20.6%) | 38 (31.2%) | | | Never | 50 (13.7%) | 11 (9%) | | | Other/no answer | 80 (21.9%) | 24 (19.7%) | |
| | Duration of initial anticoagulation for acute SVT | | | 0.14 | | 1 month or less | 69 (18.9%) | 28 (23%) | | | 1–3 months | 95 (26%) | 38 (31.2%) | | | 4–6 months | 60 (16.4%) | 17 (13.9%) | | | >6 months | 44 (12.1%) | 13 (10.7%) | | | Other/no answer | 97 (26.6%) | 26 (22.1%) | |
|
|
